GAMMACAN REPORTS PRE-IND MEETING WITH FDA REGARDING VITIGAM

A A

GammaCan International has met with the FDA to discuss requirements for the filing of an investigational new drug (IND) application for VitiGam, the company's second-generation investigational treatment for metastatic melanoma.

GammaCan is planning to initiate human clinical trials with VitiGam. Research has shown that plasma from donors with vitiligo, a benign condition affecting skin pigmentation, has anti-melanoma properties. Based on these and other findings, the company recently held a pre-IND meeting with the FDA.